Prior calcium channel blockade and short-term survival following acute myocardial infarction

Cardiovascular Drugs and Therapy

Volumn 15, Issue 6, 2001, Pages 487-492

  Parsons, Richard W ^a   Hung, Joseph ^a   Hanemaaijer, Ingrid ^a   Broadhurst, Robyn J ^a   Jamrozik, Konrad ^a   Hobbs, Michael S T ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Beta blocker; Calcium channel blocker; Case fatality; Myocardial infarction

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; NIFEDIPINE; VERAPAMIL;

ACUTE HEART INFARCTION; ADULT; ARTICLE; AUSTRALIA; CALCIUM TRANSPORT; CHANNEL GATING; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DRUG FATALITY; DRUG MECHANISM; FEMALE; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTION; PRIORITY JOURNAL; STATISTICAL ANALYSIS; SURVIVAL;

ADRENERGIC BETA-ANTAGONISTS; AUSTRALIA; CALCIUM CHANNEL BLOCKERS; DILTIAZEM; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NIFEDIPINE; ODDS RATIO; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; VERAPAMIL;

EID: 0035711619     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1013707503018     Document Type: Article

References (23)

1. Calcium channel blocking agents in the treatment of cardiovascular disorders. Part II: Hemodynamic effects and clinical applications
2. Selection of initial antihypertensive drug therapy
3. Update of calcium antagonists in myocardial infarction in light of the Second Danish Verapimil Infarction Trial (DAVIT-II) and other recent studies
4. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease
5. The effect of diltiazem on mortality and reinfarction after myocardial infarction
6. The effect of verapamil on mortality and major events after acute myocardial infarction. The Danish Verapamil Infarction Trial (DAVIT-II)
7. Long-term effects of diltiazem and verapamil on mortality and cardiac events in non-Q-wave acute myocardial infarction without pulmonary congestion: Post hoc subset analysis of the Multicenter Diltiazem Post-infarction Trial and the Second Danish Verapamil Infarction Trial studies
8. Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS-1
9. Beta blockade during and after myocardial infarction: An overview of the randomized trials
10. Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction
11. Outcome with calcium channel antagonists after myocardial infarction: A community-based study
12. 2+ antagonists will be most useful before or during early myocardial ischemia and not after infarction has been established
13. Mortality from coronary heart disease and incidence of acute myocardial infarction in Auckland, Newcastle and Perth
14. The World Health organization MONICA Project (monitoring trends and determinants in cardiovascular disease): A major international collaboration
15. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project - Registration procedures, event rates and case fatality in 38 populations from 21 countries in 4 continents
16. Trends in the treatment of non-fatal acute myocardial infarction at home in Perth, Western Australia, 1984-1993
17. Early identification of patients at low risk of death after myocardial infarction and potentially suitable for early hospital discharge
18. Reduced risk of death at 28 days in patients taking a beta-blocker before admission to hospital with myocardial infarction
19. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41 021 patients
20. Diltiazem in acute myocardial infarction treated with thrombolytic agents: A randomised placebo-controlled trial
21. Calcium antagonists and mortality in patients with coronary artery disease: A cohort study of 11,575 patients
22. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: A meta-analysis of randomised controlled trials